A qualitative study of patients’ perceptions of the value of molecular diagnosis for Familial Hypercholesterolemia (FH)

Nina Hallowell, Nicholas Jenkins, Margaret Douglas, Simon Walker, Robert Finnie, Mary Porteous, Julia Lawton

Research output: Contribution to journalArticle

11 Downloads (Pure)

Abstract

For many years Familial Hypercholesterolemia (FH), an inherited disorder, has been diagnosed using phenotypic features plus family history of early onset cardiovascular disease (CVD), and has been successfully treated using statin therapy. DNA testing is now available and this has been incorporated into familial cascade screening programmes in many parts of Europe. Little is known about patients’ perceptions of the value of undergoing molecular diagnosis for FH. In-depth interviews were carried out with patients (n=38), being treated for FH who were the first in their family to undergo DNA testing for FH. Data were analysed thematically. While interviewees regarded DNA testing as an unexceptional event, it was seen as a positive innovation because it: confirmed that their family carried a particular disorder, offered an aetiological explanation for their hypercholesterolemia and provided information about their own and family members’ future risks. From the patient perspective, the main benefit of molecular diagnosis lies in its ability to provide information which allows (younger) family members to access genetic screening and, thus, timely treatment. The implications for future developments in genetic services and the need to investigate further the provision of molecular testing in mainstream specialties are briefly discussed.
Original languageEnglish
Pages (from-to)1-8
Number of pages9
JournalJournal of Community Genetics
Early online date19 Nov 2016
DOIs
Publication statusE-pub ahead of print - 19 Nov 2016

Fingerprint

Hyperlipoproteinemia Type II
DNA
Genetic Services
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Aptitude
Genetic Testing
Hypercholesterolemia
Cardiovascular Diseases
Interviews
Therapeutics

Cite this

Hallowell, Nina ; Jenkins, Nicholas ; Douglas, Margaret ; Walker, Simon ; Finnie, Robert ; Porteous, Mary ; Lawton, Julia. / A qualitative study of patients’ perceptions of the value of molecular diagnosis for Familial Hypercholesterolemia (FH). In: Journal of Community Genetics. 2016 ; pp. 1-8.
@article{249230d2785c4afc86f17ed79fc2cc89,
title = "A qualitative study of patients’ perceptions of the value of molecular diagnosis for Familial Hypercholesterolemia (FH)",
abstract = "For many years Familial Hypercholesterolemia (FH), an inherited disorder, has been diagnosed using phenotypic features plus family history of early onset cardiovascular disease (CVD), and has been successfully treated using statin therapy. DNA testing is now available and this has been incorporated into familial cascade screening programmes in many parts of Europe. Little is known about patients’ perceptions of the value of undergoing molecular diagnosis for FH. In-depth interviews were carried out with patients (n=38), being treated for FH who were the first in their family to undergo DNA testing for FH. Data were analysed thematically. While interviewees regarded DNA testing as an unexceptional event, it was seen as a positive innovation because it: confirmed that their family carried a particular disorder, offered an aetiological explanation for their hypercholesterolemia and provided information about their own and family members’ future risks. From the patient perspective, the main benefit of molecular diagnosis lies in its ability to provide information which allows (younger) family members to access genetic screening and, thus, timely treatment. The implications for future developments in genetic services and the need to investigate further the provision of molecular testing in mainstream specialties are briefly discussed.",
author = "Nina Hallowell and Nicholas Jenkins and Margaret Douglas and Simon Walker and Robert Finnie and Mary Porteous and Julia Lawton",
year = "2016",
month = "11",
day = "19",
doi = "10.1007/s12687-016-0286-0",
language = "English",
pages = "1--8",
journal = "Journal of Community Genetics",
issn = "1868-310X",
publisher = "Springer-Verlag",

}

A qualitative study of patients’ perceptions of the value of molecular diagnosis for Familial Hypercholesterolemia (FH). / Hallowell, Nina; Jenkins, Nicholas; Douglas, Margaret; Walker, Simon; Finnie, Robert; Porteous, Mary; Lawton, Julia.

In: Journal of Community Genetics, 19.11.2016, p. 1-8.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A qualitative study of patients’ perceptions of the value of molecular diagnosis for Familial Hypercholesterolemia (FH)

AU - Hallowell, Nina

AU - Jenkins, Nicholas

AU - Douglas, Margaret

AU - Walker, Simon

AU - Finnie, Robert

AU - Porteous, Mary

AU - Lawton, Julia

PY - 2016/11/19

Y1 - 2016/11/19

N2 - For many years Familial Hypercholesterolemia (FH), an inherited disorder, has been diagnosed using phenotypic features plus family history of early onset cardiovascular disease (CVD), and has been successfully treated using statin therapy. DNA testing is now available and this has been incorporated into familial cascade screening programmes in many parts of Europe. Little is known about patients’ perceptions of the value of undergoing molecular diagnosis for FH. In-depth interviews were carried out with patients (n=38), being treated for FH who were the first in their family to undergo DNA testing for FH. Data were analysed thematically. While interviewees regarded DNA testing as an unexceptional event, it was seen as a positive innovation because it: confirmed that their family carried a particular disorder, offered an aetiological explanation for their hypercholesterolemia and provided information about their own and family members’ future risks. From the patient perspective, the main benefit of molecular diagnosis lies in its ability to provide information which allows (younger) family members to access genetic screening and, thus, timely treatment. The implications for future developments in genetic services and the need to investigate further the provision of molecular testing in mainstream specialties are briefly discussed.

AB - For many years Familial Hypercholesterolemia (FH), an inherited disorder, has been diagnosed using phenotypic features plus family history of early onset cardiovascular disease (CVD), and has been successfully treated using statin therapy. DNA testing is now available and this has been incorporated into familial cascade screening programmes in many parts of Europe. Little is known about patients’ perceptions of the value of undergoing molecular diagnosis for FH. In-depth interviews were carried out with patients (n=38), being treated for FH who were the first in their family to undergo DNA testing for FH. Data were analysed thematically. While interviewees regarded DNA testing as an unexceptional event, it was seen as a positive innovation because it: confirmed that their family carried a particular disorder, offered an aetiological explanation for their hypercholesterolemia and provided information about their own and family members’ future risks. From the patient perspective, the main benefit of molecular diagnosis lies in its ability to provide information which allows (younger) family members to access genetic screening and, thus, timely treatment. The implications for future developments in genetic services and the need to investigate further the provision of molecular testing in mainstream specialties are briefly discussed.

U2 - 10.1007/s12687-016-0286-0

DO - 10.1007/s12687-016-0286-0

M3 - Article

SP - 1

EP - 8

JO - Journal of Community Genetics

JF - Journal of Community Genetics

SN - 1868-310X

ER -